Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties.
Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DCG, Goya P, Reggio P, Martín MI, Fernández-Ruiz J, Silva AMS, Jagerovic N
ChemMedChem 7, 452-463

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington´s disease
Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, García de Yébenes J, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M
Brain 134, 119-136

Symptom-relieving and neuroprotective effects of the phytocannabinoid D9-THCV in animal models of Parkinson´s disease
García C, Palomo C, García-Arencibia M, Ramos JA, Pertwee R, Fernández-Ruiz J
British Journal of Pharmacology 163, 1495-1506

Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental Parkinsonism
Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A
Antioxidants & Redox Signaling 14, 2347-2360

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease
Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J
Journal of Neurosciences Research 89, 1509-1518

Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults
Rubio M, Villain H, Docagne F, Benoit DR, Ramos JA, Vivien D, Fernández-Ruiz J, Ali C
Plos One 6, e23690

A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.
Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, García-Arencibia M, Nuber S, Schlaudraff F, Liss B, Fernández-Ruiz J, Gerlach M, Wüllner U, Lüddens H, Calabresi P, Auburger G, Gispert S
PLOS One 5, e 11464

The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors.
Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martínez-Orgado JM
Neurobiology of Disease 37, 434-440

Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
Sagar D, Jhaveri M, Richardson D, Gray R, de Lago E, Fernández-Ruiz J, Barrett D, Kendall D, Chapman V
European Journal of Neuroscience 31, 1414-1422

Relación del sistema cannabinoide con la fisiopatología de la esquizofrenia.
Ramos, JA
Informaciones Psiquiátricas 199, 11-18

Synthesis and pharmacological evaluation of new (E)- and (Z)-3-aryl-4-styryl-1H-pyrazoles as potential cannabinoid ligands
Silva VLM, Silva AMS, Pinto DCG, Rodríguez-Valsero P, Gómez M, Jagerovic N, Callado LF, Cavaleiro JAS, Elguero J, Fernández-Ruiz J
Arkivoc X, 226-247

Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study.
Arias F, Ampuero I, Sagredo O, Almodovar F, Sánchez S, Gorgojo JJ, Ramos JA
Psychiatric Genetics, 19, 336

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity
Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I
Brain 132, 3152-3164

Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration

Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken H, Becker D, Voos W, Leuner K, Müller W, Kudin A, Kunz W, Zimmermann A, Roeper J, Wenzel D, Jendrach M, García-Arencíbia M, Fernández-Ruiz J, Huber L, Rohrer H, Barrera M, Reichert A, Rüb U, Chen A, Nussbaum R, Auburger G

PLOS One 4, e 5777

Cannabinoid CB₂ receptor agonists protect the striatum against malonate

toxicity: relevance for Huntington’s disease

Sagredo O, González S, Arroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J

Glia 57, 1154-1167

Cannabinoid CB₁ receptors are early down-regulated followed by a further up-regulation in the basal ganglia of mice with deletion of specific park genes

García-Arencibia M, García C, Kurz A, Rodríguez-Navarro JA, Gispert-Sánchez S, Mena MA, Auburger G, García de Yébenes J, Fernández-Ruiz J

Journal of Neural Transmission Supplementum 73, 269-275

Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas

Rubio M, de Miguel R, Fernández-Ruiz J, Gutiérrez-López D, Carai M, Ramos JA

Drug and Alcohol Dependence 99, 354-358

Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.

García-Arencibia M, Ferraro L, Tanganelli S, Fernández-Ruiz J

Neuroscience Letters 438, 10-13

Colocalization of CB₁ receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: evidence for a role of these receptors in axonal growth and guidance.

Gómez M, Hernández ML, Pazos MR, Tolón RM, Romero J, Fernández-Ruiz J

Neuroscience 153, 687-699

Cannabinoid CB₁ receptors are expressed by parietal cells of the human gastric mucosa.

Pazos MR, Tolón RM, Benito C, Rodríguez CF, Gorgojo JJ, Nevado M, Alvarez M, Arias F, Almodóvar F, Fernández MT, Lledó JL, González S, Fernández-Ruiz J, Romero J

J. Histochem.Cytochem 56, 511-516

CB₁ receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats

Rubio M, Fernández-Ruiz J, de Miguel R, Maestro B, Walker JM, Ramos JA

Neuropharmacology 54, 976-988

Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions.

de Lago E, Ortega-Gutiérrez S, Ramos JA, López Rodríguez ML, Fernández-Ruiz J

Life Sciences 80, 979-988.

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties.

Garcia-Arencibia M, Gonzalez S, de Lago E, Ramos JA, Mechoulam R, Fernandez-Ruiz J

Brain Research 1134, 162-170.

Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol.

Rubio M, McHugh D, Fernández-Ruiz J, Bradshaw H, Walker JM

 Neuroscience Letters 421, 270-274.

The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain.

Gómez M, Hernández M, Fernández-Ruiz J

Brain Research 1145, 48-55.

Cannabidiol reduced the striatal atrophy caused by 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.

Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J

European Journal of Neuroscience 26, 843-851.

Association in alcoholic patients between psychopathic traits and the additive effect of allelic forms of the CNR1 and FAAH endocannabinoid genes, and the 3´ region of the DRD2 gene.

Hoenicka J, Ponce G, Jiménez-Arriero MA, Ampuero I, Rodríguez-Jiménez R, Rubio G, Aragues M, Ramos JA, Palomo T

Neurotoxicity Research 11, 51-60

Chronic Delta9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex.

Sagredo O, Ramos JA, Fernandez-Ruiz J, Rodriguez ML, de Miguel R

Naunyn Schmiedebergs Arch Pharmacol. 372,313-317.

UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.

de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, Lopez-Rodriguez M, Ramos JA.

Eur Neuropsychopharmacol. 16, 7-18

Effects of rimonabant, a selective cannabinoid CB₁ receptor antagonist, in a rat model of Parkinson's disease.

Gonzalez S, Scorticati C, Garcia-Arencibia M, de Miguel R, Ramos JA, Fernandez-Ruiz J.

Brain Res. 1073-1074, 209-219

Changes in CB₁ receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice

Cabranes A, Pryce G, Baker D, Fernandez-Ruiz J.

Brain Res. 1107, 199-205.

Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations.

De Lago E, Gustafsson SB, Fernandez-Ruiz J, Nilsson J, Jacobsson SO, Fowler CJ.

J Neurochem. 99, 677-688.

Persistent penetration of MPTP through the nasal route induces Parkinson's

disease in mice.

Rojo AI, Montero C, Salazar M, Close RM, Fernández-Ruiz J, Sánchez-González MA, de Sagarra MR, Jackson-Lewis V, Cavada C, Cuadrado A.

European Journal of Neuroscience 24 , 1874-1884

Effects of inhibition of fatty acid amide hydrolase vs the anandamide membrane transporter on TRPV1-mediated calcium responses in adult DRG neurons; the role of CB₁ receptors.

Millns PJ, Chimenti M, Ali N, Ryland E, de Lago E, Fernández-Ruiz J, Chapman V, Kendall DA. European Journal of Neuroscience 24, 3489-3495

The TaqIA polymorphism linked to the DRD2 gene is related to lower attention and less inhitory control in alcoholic patients

Rodríguez-Jiménez R, Ávila C, Ponce G, Ibáñez MI, Rubio G, Jiménez-Arriero MA, Ampuero I, Ramos JA, Hoenicka J, Palomo T

European Psychiatry 21(1), 66-69

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.

Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J.

Neurobiol Dis. 19, 96-107.

Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.

Gonzalez S, Mena MA, Lastres-Becker I, Serrano A, de Yebenes JG, Ramos JA, Fernandez-Ruiz J.

Brain Res. 1046, 195-206.

Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.

de Lago E, Urbani P, Ramos JA, Di Marzo V, Fernandez-Ruiz J.

Brain Res. 1050, 210-216.

Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels.

de Lago E, Petrosino S, Valenti M, Morera E, Ortega-Gutierrez S, Fernández-Ruiz J, Di Marzo V.  Biochemical Pharmacology 70,  446-452

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.

Cabranes A, Venderova K, de Lago E, Fezza F, Sanchez A, Mestre L, Valenti M, Garcia-Merino A, Ramos JA, Di Marzo V, Fernandez-Ruiz J.

 Neurobiol Dis. 20, 207-217.